drugset / Trial / NCT04972227
Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia
RandomizedSequentialDouble-blindTreatment
Summary
The primary objective of this study is to evaluate the safety and tolerability of CY6463 when administered to participants with stable schizophrenia who are on a stable antipsychotic medication regimen
Timeline
- Start
- 2021-09-10
- Primary completion
- 2022-04-18
- Completion
- 2022-04-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | zagociguat | Small molecule | — | Oral |